Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
2.

COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.

Hochberg MC.

Curr Top Med Chem. 2005;5(5):443-8. Review.

PMID:
15974939
3.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

JAMA. 2000 Sep 13;284(10):1247-55.

PMID:
10979111
4.

Risk of cardiovascular events associated with selective COX-2 inhibitors.

Mukherjee D, Nissen SE, Topol EJ.

JAMA. 2001 Aug 22-29;286(8):954-9. Review.

PMID:
11509060
5.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
6.

Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?

Howes LG, Krum H.

Drug Saf. 2002;25(12):829-35. Review.

PMID:
12241124
8.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
9.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
10.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311
11.

NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective.

Hawkey CJ.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S23-30. Review.

PMID:
11695247
12.

Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.

Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA.

Pharmacoeconomics. 2001;19(10):1039-49.

PMID:
11735672
13.
14.
15.
16.
17.

COX-2 inhibitors. Magic bullets or merely mortal?

[No authors listed]

Harv Health Lett. 2000 Feb;25(4):4. No abstract available.

PMID:
10637015
18.

Are rofecoxib and celecoxib safer NSAIDS?

[No authors listed]

Drug Ther Bull. 2000 Nov;38(11):81-6. Review.

PMID:
11138599
19.

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS.

JAMA. 1999 Nov 24;282(20):1921-8.

PMID:
10580457
20.

Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.

Goldenberg MM.

Clin Ther. 1999 Sep;21(9):1497-513; discussion 1427-8. Review.

PMID:
10509845
Items per page

Supplemental Content

Support Center